Pooled Amplicon Deep Sequencing of Candidate Plasmodium falciparum Transmission-Blocking Vaccine Antigens.

Polymorphisms within Plasmodium falciparum vaccine candidate antigens have the potential to compromise vaccine efficacy. Understanding the allele frequencies of polymorphisms in critical binding regions of antigens can help in the designing of strain-transcendent vaccines. Here, we adopt a pooled deep-sequencing approach, originally designed to study P. falciparum drug resistance mutations, to study the diversity of two leading transmission-blocking vaccine candidates, Pfs25 and Pfs48/45. We sequenced 329 P. falciparum field isolates from six different geographic regions. Pfs25 showed little diversity, with only one known polymorphism identified in the region associated with binding of transmission-blocking antibodies among our isolates. However, we identified four new mutations among eight non-synonymous mutations within the presumed antibody-binding region of Pfs48/45. Pooled deep sequencing provides a scalable and cost-effective approach for the targeted study of allele frequencies of P. falciparum candidate vaccine antigens.

[1]  Yuming Guo,et al.  The effect of air pollution on human physiological function in China: a longitudinal study , 2015, The Lancet.

[2]  J. Bailey,et al.  Using Amplicon Deep Sequencing to Detect Genetic Signatures of Plasmodium vivax Relapse. , 2015, The Journal of infectious diseases.

[3]  Peter G. Kremsner,et al.  Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. , 2015 .

[4]  Steve M. Taylor,et al.  Absence of putative artemisinin resistance mutations among Plasmodium falciparum in Sub-Saharan Africa: a molecular epidemiologic study. , 2015, The Journal of infectious diseases.

[5]  Badria B. El-Sayed,et al.  Polymorphisms in Plasmodium falciparum Chloroquine Resistance Transporter and Multidrug Resistance 1 Genes: Parasite Risk Factors that Affect Treatment Outcomes for P. falciparum Malaria after Artemether-Lumefantrine and Artesunate-Amodiaquine , 2014, The American journal of tropical medicine and hygiene.

[6]  A. Barry,et al.  Strategies for Designing and Monitoring Malaria Vaccines Targeting Diverse Antigens , 2014, Front. Immunol..

[7]  A. Sabbagh,et al.  Genetic diversity of VAR2CSA ID1-DBL2Xb in worldwide Plasmodium falciparum populations: impact on vaccine design for placental malaria. , 2014, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[8]  Nash R. Aragam,et al.  Pooled deep sequencing of Plasmodium falciparum isolates: an efficient and scalable tool to quantify prevailing malaria drug-resistance genotypes. , 2013, The Journal of infectious diseases.

[9]  J. Bailey,et al.  Use of massively parallel pyrosequencing to evaluate the diversity of and selection on Plasmodium falciparum csp T-cell epitopes in Lilongwe, Malawi. , 2012, The Journal of infectious diseases.

[10]  Z. Premji,et al.  Plasmodium falciparum population dynamics during the early phase of anti-malarial drug treatment in Tanzanian children with acute uncomplicated malaria , 2011, Malaria Journal.

[11]  T. Bousema,et al.  The Dynamics of Naturally Acquired Immune Responses to Plasmodium falciparum Sexual Stage Antigens Pfs230 & Pfs48/45 in a Low Endemic Area in Tanzania , 2010, PloS one.

[12]  M. P. Cummings,et al.  Extreme Polymorphism in a Vaccine Antigen and Risk of Clinical Malaria: Implications for Vaccine Development , 2009, Science Translational Medicine.

[13]  S. Meshnick,et al.  Nonradioactive heteroduplex tracking assay for the detection of minority-variant chloroquine-resistant Plasmodium falciparum in Madagascar , 2009, Malaria Journal.

[14]  V. A. Stewart,et al.  Safety and Immunogenicity of an AMA-1 Malaria Vaccine in Malian Adults: Results of a Phase 1 Randomized Controlled Trial , 2008, PloS one.

[15]  H. Stunnenberg,et al.  Epitope Analysis of the Malaria Surface Antigen Pfs48/45 Identifies a Subdomain That Elicits Transmission Blocking Antibodies* , 2007, Journal of Biological Chemistry.

[16]  J. Kihonda,et al.  A longitudinal study of immune responses to Plasmodium falciparum sexual stage antigens in Tanzanian adults , 2007, Parasite immunology.

[17]  R. Carter Transmission blocking malaria vaccines. , 2001, Vaccine.

[18]  K. Mendis,et al.  Malaria transmission-blocking vaccines—how can their development be supported? , 2000, Nature Medicine.

[19]  Babita Sharma,et al.  Structure and Mechanism of a Transmission Blocking Vaccine Candidate Protein Pfs25 from P. falciparum: A Molecular Modeling and Docking Study , 2008, Silico Biol..